NRx Pharmaceuticals reports NRX-10 SPA granted in 2019 remains in effect

NRx Pharmaceuticals reported the minutes of a Type B meeting with the FDA’s Division of Psychiatry Products held on January 11. The purpose of the meeting was to discuss requirements for submission of a new drug application for NRX-101. FDA noted in written correspondence that the Special Protocol Agreement, or SPA, granted in April 2019 remains in effect. Additionally, the FDA suggested during the meeting that a broadening of the addressable population of the indication to patients with Severe Bipolar Depression and Recent Acute Suicidality regardless of how the initial stabilization was accomplished could represent a more straightforward development program. This broader indication would enable the company to potentially demonstrate the use of NRX-101 to maintain stabilization from suicidality in patients stabilized either with ketamine or with other standard of care therapeutic approaches. This broader indication is not expected to delay the acute care trial expected to be completed in 2023. FDA noted that, should the results of such a study be driven primarily by subjects stabilized with ketamine, a New Drug Application for ketamine would also be required. The FDA further guided the company to broaden the study of NRX-101 to include chronic/intermittent treatment of patients with Bipolar Depression and suicidality. This could enable a pathway for the use of NRX-101 by a broader segment of the approximately 7M individuals in the U.S. with Bipolar Disorder on a long-term basis. A portion of this population is already being addressed in the Company’s ongoing phase 2 trial, which recently passed its first Data Safety Monitoring Board, or DSMB, safety review. Based on this guidance, the Company is considering expanding its current phase 2 clinical trial to a potential registration study now that the manufacture of phase 3/commercial-stage NRX-101 has been completed. The company previously announced completion of a Type C meeting in which FDA agreed to the Company’s Chemical Manufacturing Control and stability program for drug manufacture. As previously announced, the Company currently expects a DSMB evaluation of efficacy data from this trial by the end of Q1. The FDA further advised the company that as a chronic, or chronic-intermittent treatment, the safety database requirement under ICH guidelines for NRX-101 should be 1,500 patients, with at least 100 treated for 1 year. The company is evaluating the timing and cost of expanding clinical access to this larger population. In addition to its ongoing clinical trials, the company is considering augmenting its safety database via an expanded access program, which is now enabled by the availability of commercial-stage NRX-101 and is expected under federal law governing Breakthrough Therapy Designation. The company will seek cost reimbursement for operating this Expanded Access Program as permitted under current FDA regulations. In related comments, the FDA accepted the company’s rationale for deferring pediatric and adolescent studies with NRX-101 until after drug approval and advised the company to include this rationale in its regulatory filings. The FDA will consider the company’s submission of an Advice Request to evaluate waiving or deferring chronic carcinogenicity testing as a post-approval commitment. Finally, the FDA’s Controlled Substances Staff advised the company to closely monitor abuse-related adverse events and possible cases of abuse during clinical trials.